hydroxyurea has been researched along with Skin Ulcer in 19 studies
Skin Ulcer: An ULCER of the skin and underlying tissues.
| Excerpt | Relevance | Reference |
|---|---|---|
| " She had a history of polycythemia vera and had been treated with a daily dose of 500mg hydroxyurea (HU) for six years." | 7.72 | Huge post-operative ulcer following hydroxyurea therapy in a patient with polycythemia vera. ( Iwata, K; Nakano, M; Ogawa, H; Ogura, S; Seki, K; Tasaka, T; Yokota, K, 2003) |
| "Hydroxyurea (HU) is usually a well-tolerated antineoplastic agent, which is commonly used in the treatment of myeloproliferative disorders." | 7.71 | [Hydroxyurea-induced leg ulcers in patients with chronic myeloproliferative disorders]. ( Olesen, LH; Pedersen, BB, 2001) |
| "Hydroxyurea (HU) is an established chemotherapeutic agent in the treatment of myeloproliferative disorders (MPD) including chronic myelogenous leukemia (CML), polycythemia vera and essential thrombocythemia (ET)." | 7.70 | Cutaneous ulcers associated with hydroxyurea therapy in myeloproliferative disorders. ( Cohen, P; Cortes, J; Kantarjian, H; Markowitz, A; O'Brien, S; Ravandi-Kashani, F; Talpaz, M, 1999) |
| " Pregnancy is a high-risk situation for the mother and child The efficacy and safety of hydroxyurea and long-term blood transfusions in adults with sickle cell disease are currently under investigation." | 4.84 | [New issues in adult sickle sell disease]. ( Girot, R; Lionnet, F; Stankovic, K, 2008) |
| " She had a history of polycythemia vera and had been treated with a daily dose of 500mg hydroxyurea (HU) for six years." | 3.72 | Huge post-operative ulcer following hydroxyurea therapy in a patient with polycythemia vera. ( Iwata, K; Nakano, M; Ogawa, H; Ogura, S; Seki, K; Tasaka, T; Yokota, K, 2003) |
| "Hydroxyurea (HU) is usually a well-tolerated antineoplastic agent, which is commonly used in the treatment of myeloproliferative disorders." | 3.71 | [Hydroxyurea-induced leg ulcers in patients with chronic myeloproliferative disorders]. ( Olesen, LH; Pedersen, BB, 2001) |
| "Hydroxyurea (HU) is an established chemotherapeutic agent in the treatment of myeloproliferative disorders (MPD) including chronic myelogenous leukemia (CML), polycythemia vera and essential thrombocythemia (ET)." | 3.70 | Cutaneous ulcers associated with hydroxyurea therapy in myeloproliferative disorders. ( Cohen, P; Cortes, J; Kantarjian, H; Markowitz, A; O'Brien, S; Ravandi-Kashani, F; Talpaz, M, 1999) |
| "The unusual appearance of extensive skin ulcerations was observed in 17 patients with chronic myelogenous leukemia on continuous chemotherapy with hydroxyurea." | 3.67 | Unusual dermatologic toxicity of long-term therapy with hydroxyurea in chronic myelogenous leukemia. ( Alimena, G; Carlesimo, OA; Gastaldi, R; Mandelli, F; Montefusco, E; Valesini, G, 1986) |
| "Hydroxyurea is an antitumoral drug mainly used in the treatment of Philadelphia chromosome-negative myeloproliferative syndromes and sickle-cell disease." | 2.49 | Cutaneous ulcers associated with hydroxyurea therapy. ( Barbanera, S; Dini, V; Quattrone, F; Romanelli, M; Zerbinati, N, 2013) |
| "Venous thrombosis is more frequent in PV than in ET; superficial or deep venous thromboses are seen." | 2.41 | [What vascular events suggest a myeloproliferative disorder?]. ( Caulier-Leleu, MT; Hachulla, E; Pasturel-Michon, U; Rose, C; Trillot, N, 2000) |
| " However, no epidemiologic information about the occurrence of the most clinically significant HU-associated adverse events is yet available." | 1.38 | Hydroxyurea-related toxicity in 3,411 patients with Ph'-negative MPN. ( Antonioli, E; Baccarani, M; Barbui, T; Bertozzi, I; Bosi, A; Cacciola, E; Cacciola, R; Cazzola, M; De Stefano, V; Elli, E; Finazzi, G; Finazzi, M; Guglielmelli, P; Luigia Randi, M; Martinelli, V; Passamonti, F; Pieri, L; Pogliani, E; Rambaldi, A; Rodeghiero, F; Rossi, E; Ruggeri, M; Rumi, E; Vannucchi, AM; Vianelli, N; Za, T, 2012) |
| "Hydroxyurea is a usually well-tolerated cytostatic agent, but its side effects include cutaneous lesions that appear after several years of maintenance therapy with hydroxyurea." | 1.30 | Early cutaneous lesions secondary to hydroxyurea therapy. ( Calori, R; Faccini, P; Maiolo, AT; Radaelli, F, 1998) |
| "Hydroxyurea is an effective agent in the treatment of chronic myelogenous leukemia." | 1.25 | Skin changes secondary to hydroxyurea therapy. ( Goltz, RW; Kennedy, BJ; Smith, LR, 1975) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 2 (10.53) | 18.7374 |
| 1990's | 4 (21.05) | 18.2507 |
| 2000's | 8 (42.11) | 29.6817 |
| 2010's | 5 (26.32) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Quattrone, F | 1 |
| Dini, V | 1 |
| Barbanera, S | 1 |
| Zerbinati, N | 1 |
| Romanelli, M | 1 |
| Matthews, AG | 1 |
| Wylie, G | 1 |
| Girot, R | 1 |
| Stankovic, K | 1 |
| Lionnet, F | 1 |
| Latagliata, R | 1 |
| Spadea, A | 1 |
| Cedrone, M | 1 |
| Di Giandomenico, J | 1 |
| De Muro, M | 1 |
| Villivà, N | 1 |
| Breccia, M | 1 |
| Anaclerico, B | 1 |
| Porrini, R | 1 |
| Spirito, F | 1 |
| Rago, A | 1 |
| Avvisati, G | 1 |
| Alimena, G | 2 |
| Montanaro, M | 1 |
| Andriani, A | 1 |
| Serrano-Falcón, C | 1 |
| Pugnaire, MAF | 1 |
| Del Mar Serrano-Falcón, M | 1 |
| Morales, MG | 1 |
| Serrano-Ortega, S | 1 |
| Antonioli, E | 1 |
| Guglielmelli, P | 1 |
| Pieri, L | 1 |
| Finazzi, M | 1 |
| Rumi, E | 1 |
| Martinelli, V | 1 |
| Vianelli, N | 1 |
| Luigia Randi, M | 1 |
| Bertozzi, I | 1 |
| De Stefano, V | 1 |
| Za, T | 1 |
| Rossi, E | 1 |
| Ruggeri, M | 1 |
| Elli, E | 1 |
| Cacciola, R | 1 |
| Cacciola, E | 1 |
| Pogliani, E | 1 |
| Rodeghiero, F | 1 |
| Baccarani, M | 1 |
| Passamonti, F | 1 |
| Finazzi, G | 1 |
| Rambaldi, A | 1 |
| Bosi, A | 1 |
| Cazzola, M | 1 |
| Barbui, T | 1 |
| Vannucchi, AM | 1 |
| Bravo Blanco, AM | 1 |
| Moral, JL | 1 |
| Tembrás, S | 1 |
| Gómez, R | 1 |
| Ulibarrena, C | 1 |
| Obdulia Vazquez, M | 1 |
| Yokota, K | 1 |
| Tasaka, T | 1 |
| Iwata, K | 1 |
| Ogawa, H | 1 |
| Nakano, M | 1 |
| Seki, K | 1 |
| Ogura, S | 1 |
| Geraminejad, PA | 1 |
| Walling, HW | 1 |
| Swick, BL | 1 |
| Sontheimer, RD | 1 |
| Sanchez-Palacios, C | 1 |
| Guitart, J | 1 |
| Bohn, J | 1 |
| Hansen, JP | 1 |
| Menné, T | 1 |
| Radaelli, F | 1 |
| Calori, R | 1 |
| Faccini, P | 1 |
| Maiolo, AT | 1 |
| Ravandi-Kashani, F | 1 |
| Cortes, J | 1 |
| Cohen, P | 1 |
| Talpaz, M | 1 |
| O'Brien, S | 1 |
| Markowitz, A | 1 |
| Kantarjian, H | 1 |
| McLintock, C | 1 |
| Ockelford, PA | 1 |
| Hachulla, E | 1 |
| Rose, C | 1 |
| Trillot, N | 1 |
| Caulier-Leleu, MT | 1 |
| Pasturel-Michon, U | 1 |
| Olesen, LH | 1 |
| Pedersen, BB | 1 |
| Kennedy, BJ | 1 |
| Smith, LR | 1 |
| Goltz, RW | 1 |
| Renfro, L | 1 |
| Kamino, H | 1 |
| Raphael, B | 1 |
| Moy, J | 1 |
| Sanchez, M | 1 |
| Montefusco, E | 1 |
| Gastaldi, R | 1 |
| Carlesimo, OA | 1 |
| Valesini, G | 1 |
| Mandelli, F | 1 |
4 reviews available for hydroxyurea and Skin Ulcer
| Article | Year |
|---|---|
Cutaneous ulcers associated with hydroxyurea therapy.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Female; Humans; Hydroxyurea; Male; Middle Age | 2013 |
[New issues in adult sickle sell disease].
Topics: Adult; Anemia, Sickle Cell; Blood Transfusion; Cardiomyopathies; Combined Modality Therapy; Female; | 2008 |
Hydroxyurea-associated squamous dysplasia.
Topics: Aged; Carcinoma, Squamous Cell; Humans; Hydroxyurea; Keratosis; Male; Precancerous Conditions; Skin | 2004 |
[What vascular events suggest a myeloproliferative disorder?].
Topics: Adult; Aged; Alkylating Agents; Arterial Occlusive Diseases; Cross-Sectional Studies; Erythromelalgi | 2000 |
15 other studies available for hydroxyurea and Skin Ulcer
| Article | Year |
|---|---|
Hydroxycarbamide-induced cutaneous ulceration with a difference.
Topics: Diagnosis, Differential; Drug Eruptions; Female; Hematinics; Humans; Hydroxyurea; Middle Aged; Prima | 2014 |
Symptomatic mucocutaneous toxicity of hydroxyurea in Philadelphia chromosome-negative myeloproliferative neoplasms: the Mister Hyde face of a safe drug.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Female; Humans; Hydroxyurea; Male; Middle Age | 2012 |
Toxicoderma caused by hydroxyurea.
Topics: Aged; Drug Eruptions; Female; Humans; Hydroxyurea; Nail Diseases; Pigmentation Disorders; Skin Ulcer | 2011 |
Hydroxyurea-related toxicity in 3,411 patients with Ph'-negative MPN.
Topics: Adult; Aged; Aged, 80 and over; Antimetabolites; Carcinoma, Squamous Cell; Drug Eruptions; Female; F | 2012 |
Hydroxyurea-induced skin ulcerations in patients with chronic myeloproliferative disorders.
Topics: Aged; DNA; Enzyme Inhibitors; Female; Humans; Hydroxyurea; Leg Ulcer; Male; Middle Aged; Myeloprolif | 2003 |
Huge post-operative ulcer following hydroxyurea therapy in a patient with polycythemia vera.
Topics: Aged; Anti-Bacterial Agents; Busulfan; Combined Modality Therapy; Debridement; Female; Heparin; Hern | 2003 |
Chronic penile ulceration in a 72-year-old man.
Topics: Aged; Antineoplastic Agents; Chronic Disease; Diagnosis, Differential; Drug Eruptions; Hand Dermatos | 2004 |
Ulcerative lichen planus-like dermatitis due to long-term hydroxyurea therapy.
Topics: Aged; Antineoplastic Agents; Biopsy, Needle; Diagnosis, Differential; Foot Dermatoses; Humans; Hydro | 1998 |
Early cutaneous lesions secondary to hydroxyurea therapy.
Topics: Aged; Humans; Hydroxyurea; Male; Skin Ulcer; Thrombocytosis; Time Factors | 1998 |
Cutaneous ulcers associated with hydroxyurea therapy in myeloproliferative disorders.
Topics: Adult; Aged; Antineoplastic Agents; Female; Humans; Hydroxyurea; Male; Middle Aged; Myeloproliferati | 1999 |
Hydroxyurea induced skin ulceration in myeloproliferative disorders.
Topics: Aged; Female; Humans; Hydroxyurea; Male; Middle Aged; Myeloproliferative Disorders; Nucleic Acid Syn | 2000 |
[Hydroxyurea-induced leg ulcers in patients with chronic myeloproliferative disorders].
Topics: Aged; Antineoplastic Agents; Drug Eruptions; Female; Humans; Hydroxyurea; Leg Ulcer; Leukemia, Myelo | 2001 |
Skin changes secondary to hydroxyurea therapy.
Topics: Administration, Oral; Adult; Biopsy; Female; Humans; Hydroxyurea; Leukemia, Myeloid; Leukocyte Count | 1975 |
Ulcerative lichen planus-like dermatitis associated with hydroxyurea.
Topics: Drug Eruptions; Female; Hand Dermatoses; Humans; Hydroxyurea; Leukemia, Myelogenous, Chronic, BCR-AB | 1991 |
Unusual dermatologic toxicity of long-term therapy with hydroxyurea in chronic myelogenous leukemia.
Topics: Adult; Aged; Antigen-Antibody Complex; Complement Activating Enzymes; Complement C1q; Complement C3; | 1986 |